Hinova Pharmaceuticals Inc. A

Hinova Pharmaceuticals released its 2026 semi-annual report on August 27. In the first half of the year, the company achieved total operating revenue of 54.9706 million yuan, up 317.48 percent year on year. However, net profit attributable to the parent company showed a loss of 56.2181 million yuan, compared with a loss of 61.8532 million yuan in the same period last year, narrowing the loss. Net profit after deducting non-recurring items was a loss of 67.5744 million yuan, compared with a loss of 73.0056 million yuan a year earlier. Net cash flow from operating activities was negative 46.3941 million yuan, compared with negative 47.428 million yuan in the prior-year period. Basic earnings per share were negative 0.57 yuan, and the weighted average return on net assets was negative 5.43 percent. As of the end of the first half of 2026, the company's inventory book value was 15.2948 million yuan, accounting for 1.52 percent of net assets, an increase of 12.4492 million yuan from the end of last year. No inventory write-down provision was made during the period.

Hinova Pharmaceuticals released its 2026 interim report, showing total operating revenue of 54.9706 million yuan, net profit attributable to the parent company of negative 56.2181 million yuan, and net cash flow from operating activities of negative 46.3941 million yuan. The company's latest asset-liability ratio is 20.86%, gross margin is 97.34%, return on equity is negative 5.58%, and diluted earnings per share is negative 0.57 yuan. The number of shareholders is 7,146, and the top ten shareholders hold 37.71% of total share capital.